BeOne Medicines (BEIGF) Total Non-Current Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Total Non-Current Liabilities data on file, last reported at $2.0 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $2.0 billion, up 453.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 453.09% YoY), and the FY2025 annual result was $2.0 billion, up 434.67% from the prior year.
• Total Non-Current Liabilities declined to $2.0 billion in Q1 2026 per BEIGF's latest filing, from $2.0 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.0 billion in Q4 2025 and troughed at $318.1 million in Q2 2025.
• A 5-year average of $705.7 million and a median of $525.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities sank 34.35% in 2022, then surged 453.09% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $527.4 million in 2022, then decreased by 13.19% to $457.8 million in 2023, then retreated by 18.36% to $373.8 million in 2024, then jumped by 434.67% to $2.0 billion in 2025, then retreated by 0.84% to $2.0 billion in 2026.
• Business Quant data shows BEIGF's Total Non-Current Liabilities at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.1 billion in Q3 2025.